Overview | Day 1 | Day 2 | Download Brochure

• RNAi Screens For Target Identification  and Validation
• High-Throughput Functional Screens
• RNAi Screens for Pathway Analysis
 

Executive Forum:
RNAI: How to Best Transition From The Lab to the Clinic

 

undefinedBob Brown, Ph.D., Senior Vice President for Research, Dicerna Pharmaceuticals

 

 

 

Thomas SingerThomas Singer D.A.B.T., Global Head  of Non-Clinical Safety, F. Hoffmann-La Roche AG

 

 

 

Elena FeinsteinElena Feinstein, M.D., Chief Scientific  Officer, Quark Pharmaceuticals Inc.

 

 

 


Steven QuaySteven C. Quay, M.D., Ph.D., Chairman and Chief Scientific Officer, MDRNA Inc.

 

 


Tod WoolfTod Woolf, Ph.D., President and Chief Executive Officer, RXi Pharmaceuticals

 


 


Klaus GieseKlaus Giese, Ph.D., Chief Scientific  Officer, Silence Therapeutics PLC

 

DISTINGUISHED FACULTY

Roderick L. Beijersbergen, Ph.D.,  The Netherlands Cancer Institute

Michael Boutros, Ph.D., German Cancer Research Center (invited)

Christophe J. Echeverri, Ph.D., Cenix BioScience GmbH

Stephen J. Elledge, Ph.D., Harvard  Medical School

Marc Ferrer, Ph.D., Merck & Co.

Alex Gaither, Ph.D., Novartis Institutes for Biomedical Research

Richard Janssen, Ph.D., BioFocus DPI, A Galapagos Company

Paul D. Kassner, Ph.D., Amgen Inc.

Xiaoyu Lin, Ph.D., Abbott Laboratories

Nikolaus Machuy, Ph.D., Max-Planck Institute for Infection Biology

Jeff MacKeigan, Ph.D., Van Andel  Research Institute

Muthiah Manoharan, Ph.D., Alnylam Pharmaceuticals

Ian McLachlan, Ph.D., Protiva  Biotherapeutics (invited)

Norbert Perrimon, Ph.D., Harvard  Medical School

Quick Que, Ph.D., Translational Genomics Research Institute

Michael White, Ph.D., University of  Southwestern Medical Center


 

PRE-CONFERENCE SHORT COURSE*



MONDAY, OCTOBER 20

 

2:00 – 5:00
(SC4) Tackling RNAi Delivery
The course is designed to provide both the beginner and the expert, with a comprehensive overview of current and emerging delivery systems and formulations facilitating RNAi delivery. Various methods for RNAi delivery such as viral vectors, liposomes, nanoparticles, chemical conjugates and other commonly used techniques will be compared
and contrasted for different applications. The instructors will also discuss the challenges associated with the delivery of a wide-array of RNA molecules such as siRNAs,
shRNAs, aptamers and miRNAs and offer guidance based on their knowledge and expertise in the field. The course is offered in an informal and interactive setting to enable free
exchange of ideas and information.


Topics to be covered:

  • Testing and validating methods for delivery
  • Overview of viral and non-viral vector systems
  • Chemical methods of improving delivery
  • New formulations to optimize delivery
  • Minimizing cytotoxicity and off-target effects
  • Examining tissue distribution and safety profile


Tutors:
Muthiah Manoharan Ph.D., Vice President, Drug Discovery, Alnylam Pharmaceuticals
Ian McLachlan, Ph.D., Chief Scientific Officer, Protiva Biotherapeutics Inc. (invited)


*separate registration required


4:00-6:00 Main Conference Early Registration